|
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
RECRUITINGPhase 1Sponsored by Damora Therapeutics
Actively Recruiting
PhasePhase 1
SponsorDamora Therapeutics
Started2026-09
Est. completion2030-06
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations25 sites
View on ClinicalTrials.gov →
NCT07849231
Summary
This is a multi-center, open-label, Phase 1/1b study designed to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DMR-001 monotherapy in adult participants with CALR-mutated essential thrombocythemia (ET) and myelofibrosis (MF), and of DMR-001 in combination with ruxolitinib in participants with CALR-mutant MF.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and the protocol. * Diagnosis/confirmation of ET or MF as defined in the protocol. * Documented CALR exon-9 mutation. * Willingness to undergo bone marrow biopsy and aspiration per the Schedule of Assessments. Exclusion Criteria: * Presence of any malignancy unless participant has been disease free for at least 2 years. * History of major bleeding or thrombosis within the last 3 months prior to study enrollment. * Prior hematopoietic stem cell transplantation or donor leukocyte infusion, or such transplantation or infusion is planned. * Participants with laboratory values exceeding protocol defined thresholds. * History of clinically significant or uncontrolled cardiac disease. * Active HBV, HCV or HIV. * Known hypersensitivity to DMR-001 or ruxolitinib or any of their components. Other protocol defined Inclusion/Exclusion Criteria may apply.
Conditions2
CancerMyeloproliferative Neoplasms (MPNs)
Interventions2
Locations25 sites
Site US07
Site US26
Site US11
Site US25
Find trials near these locations
Cancer trials in TampaCancer trials in AtlantaCancer trials in BaltimoreCancer trials in BostonCancer trials in New YorkCancer trials in CharlotteCancer trials in ColumbusCancer trials in NashvilleCancer trials in HoustonCancer trials in SeattleAll trials in AlabamaAll trials in ArizonaAll trials in CaliforniaAll trials in FloridaAll trials in GeorgiaAll trials in KansasAll trials in MarylandAll trials in MassachusettsAll trials in MichiganAll trials in MissouriAll trials in New YorkAll trials in North CarolinaAll trials in OhioAll trials in OregonAll trials in TennesseeAll trials in TexasAll trials in UtahAll trials in VirginiaAll trials in Washington
Related trials
- BeFluBu vs FluBuRux Conditioning in Haploidentical HCT — St. Petersburg State Pavlov Medical University
- HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies — Princess Maxima Center for Pediatric Oncology
- MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera — University of Birmingham
- MRD-positive AML Clinical Study — Institute of Hematology & Blood Diseases Hospital, China
- Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor — St. Petersburg State Pavlov Medical University
- Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV — Institute of Hematology & Blood Diseases Hospital, China
- Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation — Hannah Choe, MD
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma — Mayo Clinic
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 1
SponsorDamora Therapeutics
Started2026-09
Est. completion2030-06
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations25 sites
View on ClinicalTrials.gov →
NCT07849231